Drug Detail

Information about CS1001

Generic Name
IND	CS1001
Brand Name (US)
Manufacturer	CStone Pharmaceuticals
Drug Type	Immunotherapy
Delivery	Intravenous
Approval Status	CS1001 is in Phase 3
Indications
Overall Strategy	Immune system
Strategy	Immune checkpoint inhibitor
Drug Category	PDL-1 inhibitor

Links
	CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

Trials of this drug
Trial results